Related Experiment Video
Updated: Oct 16, 2025
One-day Workflow Scheme for Bacterial Pathogen Detection and Antimicrobial Resistance Testing from Blood Cultures
Published on: July 9, 2012
Using Molecular Diagnostics to Develop Therapeutic Strategies for Carbapenem-Resistant Gram-Negative Infections
1Cepheid, Sunnyvale, CA, United States.
Abstract:
Infections caused by multidrug-resistant Gram-negative organisms have become a global threat. Such infections can be very difficult to treat, especially when they are caused by carbapenemase-producing organisms (CPO). Since infections caused by CPO tend to have worse outcomes than non-CPO infections, it is important to identify the type of carbapenemase present in the isolate or at least the Ambler Class (i.e., A, B, or D), to optimize therapy. Many of the newer beta-lactam/beta-lactamase inhibitor combinations are not active against organisms carrying Class B metallo-enzymes, so differentiating organisms with Class A or D carbapenemases from those with Class B enzymes rapidly is critical. Using molecular tests to detect and differentiate carbapenem-resistance genes (CRG) in bacterial isolates provides fast and actionable results, but utilization of these tests globally appears to be low. Detecting CRG directly in positive blood culture bottles or in syndromic panels coupled with bacterial identification are helpful when results are positive, however, even negative results can provide guidance for anti-infective therapy for key organism-drug combinations when linked to local epidemiology. This perspective will focus on the reluctance of laboratories to use molecular tests as aids to developing therapeutic strategies for infections caused by carbapenem-resistant organisms and how to overcome that reluctance.
Insights
Molecular tests rapidly detect carbapenem-resistance genes (CRG) in Gram-negative organisms, aiding treatment. Overcoming laboratory reluctance to use these tests is crucial for optimizing therapy against multidrug-resistant infections.
Area of Science:
- Microbiology
- Infectious Diseases
- Molecular Diagnostics
Background:
- Multidrug-resistant Gram-negative organisms, particularly carbapenemase-producing organisms (CPO), pose a significant global health threat.
- Infections caused by CPO are associated with poorer patient outcomes compared to non-CPO infections.
- Accurate and rapid identification of carbapenemase types (Ambler Classes A, B, or D) is essential for effective antimicrobial therapy selection.
Purpose of the Study:
- To highlight the critical need for molecular tests in identifying carbapenem-resistance genes (CRG).
- To address the low global utilization of molecular tests for guiding therapy against carbapenem-resistant organisms.
- To explore strategies for overcoming laboratory reluctance in adopting these diagnostic tools.
Main Methods:
- Focus on the utility of molecular tests for detecting and differentiating CRG in bacterial isolates.
- Discuss the application of these tests directly in positive blood cultures and syndromic panels.
- Emphasize the value of both positive and negative molecular test results in conjunction with local epidemiology.
Main Results:
- Molecular tests offer fast and actionable results for detecting carbapenem-resistance genes (CRG).
- Differentiating Class B carbapenemases from Classes A and D is critical due to the limited activity of newer beta-lactam/beta-lactamase inhibitor combinations against Class B.
- Even negative molecular results, when combined with epidemiological data, can inform anti-infective treatment strategies.
Conclusions:
- Molecular detection of CRG is vital for optimizing treatment of multidrug-resistant Gram-negative infections.
- Addressing the reluctance of laboratories to adopt molecular diagnostics is key to improving patient care.
- Integrating molecular test results with epidemiological data enhances therapeutic decision-making for carbapenem-resistant organism infections.
More Related Videos
Related Concept Videos
01:29Modern Molecular Taxonomy
01:20Applications of Molecular Taxonomy
01:30Development of Antibiotic Resistance